Emerging antiviral therapeutics for human adenovirus infection: Recent developments and novel strategies

Mackenzie J Dodge; Katelyn M MacNeil; Tanner M Tessier; Jason B Weinberg; Joe S Mymryk

doi:10.1016/j.antiviral.2021.105034

Emerging antiviral therapeutics for human adenovirus infection: Recent developments and novel strategies

Antiviral Res. 2021 Apr:188:105034. doi: 10.1016/j.antiviral.2021.105034. Epub 2021 Feb 10.

Authors

Mackenzie J Dodge¹, Katelyn M MacNeil¹, Tanner M Tessier¹, Jason B Weinberg², Joe S Mymryk³

Affiliations

¹ Department of Microbiology and Immunology, The University of Western Ontario, London, ON, Canada.
² Department of Pediatrics, University of Michigan, Ann Arbor, MI, USA; Department of Microbiology and Immunology, University of Michigan, Ann Arbor, MI, USA.
³ Department of Microbiology and Immunology, The University of Western Ontario, London, ON, Canada; Department of Otolaryngology, Head & Neck Surgery, The University of Western Ontario, London, ON, Canada; Department of Oncology, The University of Western Ontario, London, ON, Canada; London Regional Cancer Program, Lawson Health Research Institute, London, ON, Canada. Electronic address: jmymryk@uwo.ca.

Abstract

Human adenoviruses (HAdV) are ubiquitous human pathogens that cause a significant burden of respiratory, ocular, and gastrointestinal illnesses. Although HAdV infections are generally self-limiting, pediatric and immunocompromised individuals are at particular risk for developing severe disease. Currently, no approved antiviral therapies specific to HAdV exist. Recent outbreaks underscore the need for effective antiviral agents to treat life-threatening infections. In this review we will focus on recent developments in search of potential therapeutic agents for controlling HAdV infections, with a focus on those targeting post-entry stages of the virus replicative cycle.

Keywords: Adenovirus; Antiviral; Cidofovir; Drug repurposing; Drug synergy; Host-pathogen interactions; Outbreak; Synthetic-lethal.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review

MeSH terms

Active Transport, Cell Nucleus / drug effects
Adenovirus Infections, Human / drug therapy*
Adenovirus Infections, Human / virology
Adenoviruses, Human / drug effects*
Adenoviruses, Human / genetics
Adenoviruses, Human / physiology
Antiviral Agents / pharmacology
Antiviral Agents / therapeutic use*
DNA Replication / drug effects
Drug Repositioning
Drug Therapy, Combination
Epigenesis, Genetic / drug effects
Gene Expression / drug effects
Humans
Immunotherapy, Adoptive
T-Lymphocytes / immunology
Virus Replication / drug effects

Substances

Antiviral Agents

Abstract

Publication types

MeSH terms

Substances

Grants and funding